Page last updated: 2024-11-11

(S)-nadifloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

levonadifloxacin: broad-spectrum anti-MRSA benzoquinolizine quinolone agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9850038
CHEMBL ID190561
CHEBI ID37908
SCHEMBL ID36594

Synonyms (32)

Synonym
CHEBI:37908 ,
(s)-nadifloxacin
(5s)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1h,5h-pyrido[3,2,1-ij]quinoline-2-carboxylic acid
CHEMBL190561
levonadifloxacin [inn]
154357-42-3
levonadifloxacin
(s)-(-)-nadifloxacin
8whh66l098 ,
unii-8whh66l098
1h,5h-benzo[ij]quinolizine-2-carboxylicacid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5s)-
1h,5h-benzo(ij)quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (s)-
(5s)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1h,5h-benzo(ij)quinolizine-2-carboxylic acid
nadifloxacin, (s)-
wck-771 free base
levonadifloxacin [who-dd]
1h,5h-benzo(ij)quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (5s)-
(5s)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1h,5h-benzo(ij)quinolizine-2-carboxylic acid
(s)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1h,5h-pyrido(3,2,1-ij)quinoline-2-carboxylic acid
wck771 free base
SCHEMBL36594
DTXSID70165599
Q27117310
(12s)-7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
(s)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1h,5h-pyrido[3,2,1-ij]quinoline-2-carboxylic acid
wck771
gtpl10757
F82021
MS-25695
CS-0003639
HY-14926
STARBLD0002875

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Safety pharmacology studies following single dose revealed no adverse effects on central nervous system (including seizure) in mice and cardiovascular system (hERG and monkey telemetry)."( Preclinical safety evaluation of levonadifloxacin, a novel anti-methicillin-resistant Staphyloccocus aureus benzoquinolizine fluoroquinolone by intravenous and oral administration.
Gupta, S; Kansagara, A; Nandanwar, M; Patel, A; Patel, M; Patel, MA; Thorve, D; Yeole, R, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" In repeat-dose toxicity studies, except for IV bolus dosing related effects in rat (hyperactivity, mild convulsion, polypnoea and injection site irritation) and dog (emesis and salivation), no other adverse findings limiting the dosing duration were observed."( Preclinical safety evaluation of levonadifloxacin, a novel anti-methicillin-resistant Staphyloccocus aureus benzoquinolizine fluoroquinolone by intravenous and oral administration.
Gupta, S; Kansagara, A; Nandanwar, M; Patel, A; Patel, M; Patel, MA; Thorve, D; Yeole, R, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nadifloxacin
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID246899Protection of mice infected with MRSA-32 cell suspension after oral administration of compound2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID245346Minimum inhibitory concentration against methicillin susceptible Staphylococcus aureus in the absence of esterase action2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1890598Antibacterial activity against Streptococcus pneumoniae assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI based serial agar dilution method2022Bioorganic & medicinal chemistry letters, 05-01, Volume: 63WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
AID246900Protection of mice infected with MRSA-32 cell suspension after s.c. administration of compound2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID1890597Antibacterial activity against methicillin resistant Staphylococcus aureus assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI based serial agar dilution method2022Bioorganic & medicinal chemistry letters, 05-01, Volume: 63WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's2 (15.38)24.3611
2020's10 (76.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.64 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index5.53 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.25%)5.53%
Reviews4 (25.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (68.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]